CytoDyn (CYDY) Operating Expenses (2010 - 2026)

CytoDyn (CYDY) has 17 years of Operating Expenses data on file, last reported at $6.3 million in Q1 2026.

• Quarterly Operating Expenses rose 57.46% year-over-year to $6.3 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was $38.0 million (up 569.57% YoY) and the FY2025 annual result came in at -$9.7 million, down 153.5% from the prior year.
• Operating Expenses eased to $6.3 million in Q1 2026, from $21.7 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $79.0 million in Q2 2022 to a low of -$22.4 million in Q3 2024.
• A 5-year average of $10.6 million and a median of $4.9 million in 2025 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2024 — Operating Expenses sank 586.49% — and 2025, when it soared 485.06%.
• Tracing CYDY's Operating Expenses over 5 years: stood at $23.2 million in 2022, then sank by 85.33% to $3.4 million in 2023, then gained by 9.09% to $3.7 million in 2024, then soared by 485.06% to $21.7 million in 2025, then slumped by 70.94% to $6.3 million in 2026.
• The last three Operating Expenses figures came in at $6.3 million (Q1 2026), $21.7 million (Q4 2025), and $4.9 million (Q3 2025), per Business Quant data.